Evidence map›Paper›PMID 35294121›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2022

Shenweifang-containing serum inhibits transforming growth factor-β1 induced myofibroblast differentiation in normal rat kidney interstitial fibroblast cell.

Jiaru Lin, Li Wang, Bo Chen, Santao Ou, Jianhua Qin, Junming Fan

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jiaru LinDepartment of Nephrology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Li WangCentral Laboratory, the Affiliated Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China.
Bo ChenCentral Laboratory, the Affiliated Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China.
Santao OuDepartment of Nephrology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Jianhua QinDepartment of Nephrology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Junming FanSouthwest Medical University, Luzhou 646000, China.
Affiliated Hospital of Southwest Medical University · CNSouthwest Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the efficacy of Shenweifang (SWF)-containing serum on transforming growth factor (TGF)-β1-induced fibroblast-myofibroblast transition in normal rat kidney interstitial fibroblast cells (NRK-49F).

methodsSprague-Dawley rats were gavaged with one of five solutions: (a) saline; (b) saline plus low-dose SWF; (c) saline plus medium-dose SWF; (d) saline plus highdose SWF; and (e) saline plus valsartan. NRK-49F cells were treated with TGF-β1 and cultured using serum from the gavaged rats.

resultsTGF-β1 treatment increased the expression of α-smooth muscle actin, proliferating cell nuclear antigen, collagen I, Smad3, mitogen-activated protein kinase (MAPK) 10, and c-Jun N-terminal kinase (JNK) 3 and induced abnormalities in cell morphology, cell cycle progression, and cell proliferation.

conclusionsSWF- or valsartan-containing serum corrected (or partially corrected) TGF-β1-induced abnormal changes in this in vitro system. SWF-containing serum reversed abnormalities in morphology, cell cycle progression, and proliferation in TGF-β1-treated NRK49F cells, probably by blocking the TGF-β1/Smads and TGF-β1/MAPK/JNK pathways.

Indexed as

MyofibroblastsTransforming Growth Factor beta1AnimalsCell DifferentiationFibroblastsHumansKidneyRatsRats, Sprague-DawleyValsartanTransforming Growth Factor beta1ValsartanFibrosiJNK mitogenactivated proteinKinases drug-containing serumShenweifangSmad proteins; mitogen-activated protein kinaseTransforming growth factor beta1

Identifiers

PMID35294121
PMCPMC10164629
OpenAlexW4220877658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.